Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Comparison of lentiviral promoters on the therapeutic efficacy of tri-specific CAR-T cells targeting CD19/CD20/CD22

Yang Liu, Borwyn Wang, Jessica Morris, Olivia Wise-Dent, Yanping Xie, Gregory Sowd, JiHyun Kim, Xiaorong Wu, Maggie Yates, Beatrix Ferencz, Ibeawuchi Oparaocha, Oxana Slessareva, Zhongyu Zhu, Boro Dropulic, Ying Xiong

Blood (2025) 146 (Supplement 1): 7706.

https://doi.org/10.1182/blood-2025-7706

Published: 2025

Journal Articles

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Arun Arunachalam, Jessica Kerr, Jane Reese, Armin Ghobadi, David Wald, Rimas Orentas, Boro Dropulic, Paolo Caimi, Marcos de Lima, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 567.

https://doi.org/10.1182/blood-2025-567

Published: 2025

Journal Articles

Optimization of Lentiviral ß-Globin Vectors in a Forward Orientation to Enhance Therapeutic Effectiveness for Sickle Cell Disease

Jennifer Okalova, Jordan Shields Alexander, Christopher Chambliss, Zhongyu Zhu, Yanping Xie, Matthew Addington-Hall, Oxana Slessareva, Tony Luo, Beatrix Ferencz, Ibeawuchi Oparaocha, Naoya Uchida, John F. Tisdale, Boro Dropulic, H. Trent Spencer, Rimas J Orentas, David R Archer

Blood (2023) 142 (Supplement 1): 5002.

https://doi.org/10.1182/blood-2023-187506

Published: 2023

Journal Articles

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Paolo F Caimi, Martina Di Trani, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Kirsten M Boughan, Molly Gallogly, Leland Metheny, Brenda W. Cooper, Boro Dropulic, Marcos J.G. de Lima, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 7457–7459.

https://doi.org/10.1182/blood-2022-170629

Published: 2022

Journal Articles

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Sumithira Vasu, Lapo Alinari, Nicole Szuminski, Dina Schneider, Nathan Denlinger, Wing Keung Chan, Khalid Parris, Nidhi Sharma, Hillary Bradbury, Beth Daneault, Lynn O'Donnell, Boro Dropulic, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 7474–7475.

https://doi.org/10.1182/blood-2022-167340

Published: 2022

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

Zachary Jackson, Changjin Hong, Robert Schauner, Boro Dropulic, Paolo F. Caimi, Marcos J.G. de Lima, Kalpana Gupta, Jane Reese, Tae Hyun Hwang, David Wald

Blood (2021) 138 (Supplement 1): 164.

https://doi.org/10.1182/blood-2021-152813

Published: 2021

Journal Articles

A Fully-Human Armored BCMA CAR Boosts Function of CD4 + CAR-T Cells and Resists TGF-β Suppression in Pre-Clinical Models of Multiple Myeloma

Leah Alabanza, PhD, Bang Vu, PhD, Darong Wu, MS, Zhongyu Zhu, PhD, Boro Dropulic, PhDMBA, Dina Schneider, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-141062

Published: 2020

Journal Articles

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Paolo F Caimi, MD, Ashish Sharma, Patricio Rojas, MD, Seema Patel, PharmD, Jane Reese, Folashade Otegbeye, MBBChir,MPH, Andrew Worden, Michael Kadan, Michael Maschan, MD PhD, Rimas J Orentas, PhD, Boro Dropulic, PhDMBA, Rafick Sekaly, Marcos de Lima, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-143114

Published: 2020

Journal Articles

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

Tyce Kearl, MD PhD, Ao Mei, Ryan Brown, Bryon Johnson, PhD, Dina Schneider, PhD, Boro Dropulic, PhDMBA, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD, Subramaniam Malarkannan, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142937

Published: 2020

Journal Articles

Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial

Huiqing Xu, MD, Katherine Chaney, MS, Bryon Johnson, PhD, Timothy S. Fenske, MD, Mehdi Hamadani, MD, Boro Dropulic, PhDMBA, Dina Schneider, PhD, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-136805

Published: 2020

Journal Articles

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-136067

Published: 2020

Journal Articles

Fully Human Tandem CD22-CD19 CAR-T Cells with Superior Sensitivity to Low Antigen Density Derived by Optimization of Co-Stimulation and CAR Architecture

Peirong Hu, PhD, Ying Xiong, PhD, Darong Wu, MS, Zhongyu Zhu, PhD, Boro Dropulic, PhDMBA, Dina Schneider, PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140836

Published: 2020

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Blood (2019) 134 (Supplement_1): 2625.

https://doi.org/10.1182/blood-2019-130370

Published: 2019

Journal Articles

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Fenlu Zhu, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Walter L. Longo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Boro Dropulic, PhD, Rimas J Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2019) 134 (Supplement_1): 4465.

https://doi.org/10.1182/blood-2019-125328

Published: 2019

Journal Articles

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Nirav N Shah, MD, Fenlu Zhu, PhD, Carolyn Taylor, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Sharon Yim, Timothy S. Fenske, MD, Mehdi Hamadani, MD, Bryon Johnson, PhD, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 4193.

https://doi.org/10.1182/blood-2018-99-110194

Published: 2018

Journal Articles

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Fenlu Zhu, PhD, Nirav N Shah, MD, Dina Schneider, PhD, Huiqing Xu, MD, Katherine Chaney, MS, Lawrence Luib, MS, Carolyn A. Keever-Taylor, DPhil, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2018) 132 (Supplement 1): 4553.

https://doi.org/10.1182/blood-2018-99-116566

Published: 2018

Journal Articles

Title Point-of-Care Production of CD19 CAR-T Cells in an Automated Closed-System: Report of First Clinical Experience

Olga Molostova, MD, Larisa Shelikhova, MD, Yakov Muzalevsky, Alexey Kazachenok, Dmitriy Pershin, Elena Kurnikova, Alexander Popov, MD PhD, Boro Dropulic, PhD, Dina Shneider, Rimas Orentas, PhD, Regina Alex, Mike Essl, Natalia Miakova, MD PhD, Dmitry Litvinov, MD PhD, Alexander Karachunskiy, MD PhD, Galina Novichkova, MD PhD, Alexey A. Maschan, MD, Michael Maschan, MD PhD

Blood (2018) 132 (Supplement 1): 5202.

https://doi.org/10.1182/blood-2018-99-118282

Published: 2018

Journal Articles

CAR-T Cell Production Using the Clinimacs ® Prodigy System

Fenlu Zhu, PhD, Nirav N. Shah, MD MSHP, Huiqing Xu, MD, Dina Schneider, Rimas Orentas, PhD, Boro Dropulic, Parameswaran Hari, MD MRCP, MS, Carolyn A. Keever-Taylor, PhD

Blood (2016) 128 (22): 5724.

https://doi.org/10.1182/blood.V128.22.5724.5724

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparison of lentiviral promoters on the therapeutic efficacy of tri-specific CAR-T cells targeting CD19/CD20/CD22

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Optimization of Lentiviral ß-Globin Vectors in a Forward Orientation to Enhance Therapeutic Effectiveness for Sickle Cell Disease

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

A Fully-Human Armored BCMA CAR Boosts Function of CD4 + CAR-T Cells and Resists TGF-β Suppression in Pre-Clinical Models of Multiple Myeloma

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Fully Human Tandem CD22-CD19 CAR-T Cells with Superior Sensitivity to Low Antigen Density Derived by Optimization of Co-Stimulation and CAR Architecture

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Title Point-of-Care Production of CD19 CAR-T Cells in an Automated Closed-System: Report of First Clinical Experience

CAR-T Cell Production Using the Clinimacs ® Prodigy System

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only